Transcriptomics

Dataset Information

2

Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma either responsive or resistant to trabectedin treatment.


ABSTRACT: Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma with either FUS-CHOP type I, named as ML017, or FUS-CHOP type III, named as ML006. Both ML017 and ML006 are responsive to trabectedin treatment, while model ML017/ET has aquired resistance to the drug. Samples are either under untreated conditions, or treated either with trabectedin or pioglitazone or both.

ORGANISM(S): Homo sapiens  

SUBMITTER: Laura Mannarino  

PROVIDER: E-MTAB-8632 | ArrayExpress | 2020-01-10

REPOSITORIES: ArrayExpress

altmetric image

Publications


BACKGROUND:Myxoid liposarcoma is a histological subtype of liposarcoma particularly sensitive to trabectedin. In clinical use this drug does not cause cumulative toxicity, allowing prolonged treatment, generally until disease progression. No other effective therapies are available for trabectedin-resistant patients. METHODS:Through repeated in vivo treatment in athymic nude mice, we have obtained a patient-derived xenograft with acquired resistance to trabectedin. RESULTS:At basal level, the mor  ...[more]

Publication: 1/2

Similar Datasets

2010-07-13 | E-GEOD-20350 | ArrayExpress
2010-07-13 | GSE20350 | GEO
2018-01-15 | E-MTAB-5366 | ArrayExpress
2013-12-10 | E-MTAB-1809 | ArrayExpress
2017-07-25 | E-MTAB-5366 | ExpressionAtlas
2017-04-30 | E-MTAB-2979 | ArrayExpress
2016-12-14 | E-MTAB-2978 | ArrayExpress
2011-09-30 | E-GEOD-32441 | ArrayExpress
| GSE76981 | GEO
| GSE77175 | GEO